

**Table 4.2**  
**Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for SRC Super Cohort Participants<sup>1</sup> Who Did Not Report a Prevalent Condition at Baseline**

Data as of: March 1, 2019; Events through March 1, 2019

Outcome	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
<b>Number of participants</b>	117634	14781	22638	53171	27044
<b>Mean follow-up (months)</b>	193.1	221.2	215.9	194.7	155.6
DVT	4123 (0.23%)	360 (0.14%)	650 (0.16%)	2056 (0.25%)	1057 (0.32%)
Pulmonary embolism <sup>2</sup>	2560 (0.14%)	229 (0.08%)	449 (0.11%)	1304 (0.15%)	578 (0.17%)
Angina (hospitalized) <sup>3</sup>	8658 (0.48%)	751 (0.28%)	1464 (0.37%)	4344 (0.53%)	2099 (0.65%)
Diabetes (treated)	16173 (0.88%)	2194 (0.82%)	3401 (0.85%)	7638 (0.91%)	2940 (0.87%)
Hysterectomy	6878 (0.61%)	1071 (0.63%)	1674 (0.64%)	3139 (0.62%)	994 (0.50%)
Osteoarthritis <sup>4</sup>	37408 (3.33%)	5754 (2.89%)	8439 (3.11%)	16792 (3.46%)	6423 (3.81%)
Intestinal polyps	29966 (1.73%)	4608 (1.77%)	6976 (1.82%)	13631 (1.75%)	4751 (1.56%)
Lupus	1923 (0.10%)	248 (0.09%)	398 (0.10%)	891 (0.10%)	386 (0.11%)
Hypertension treated w/pills	44936 (3.19%)	5700 (2.46%)	9176 (2.80%)	20800 (3.34%)	9260 (4.07%)
COPD <sup>5</sup>	7100 (0.90%)	832 (0.76%)	1495 (0.91%)	3753 (1.05%)	1020 (0.69%)
Macular degeneration <sup>6</sup>	16789 (1.30%)	1200 (0.66%)	2474 (0.91%)	8621 (1.47%)	4494 (1.90%)
Dementia <sup>6</sup>	12157 (0.94%)	505 (0.28%)	1284 (0.47%)	6328 (1.08%)	4040 (1.71%)
Parkinson's disease <sup>6</sup>	2156 (0.17%)	153 (0.08%)	377 (0.14%)	1208 (0.21%)	418 (0.18%)

Outcomes	Race/Ethnicity			
	American Indian/ Alaskan Native	Asian/Pacific Islander	White	Unknown
<b>Number of participants</b>	583	3663	111511	1877
<b>Mean follow-up (months)</b>	160.9	165.6	194.6	170.2
DVT	11 (0.15%)	36 (0.07%)	4022 (0.23%)	54 (0.21%)
Pulmonary embolism <sup>2</sup>	9 (0.12%)	20 (0.04%)	2506 (0.14%)	25 (0.09%)
Angina (hospitalized) <sup>3</sup>	43 (0.61%)	133 (0.27%)	8363 (0.48%)	119 (0.47%)
Diabetes (treated)	107 (1.52%)	542 (1.12%)	15233 (0.86%)	291 (1.14%)
Hysterectomy	17 (0.45%)	123 (0.37%)	6647 (0.62%)	91 (0.58%)
Osteoarthritis <sup>4</sup>	150 (3.46%)	1161 (3.20%)	35511 (3.33%)	586 (3.56%)
Intestinal polyps	126 (1.76%)	763 (1.67%)	28650 (1.73%)	427 (1.77%)
Lupus	16 (0.21%)	41 (0.08%)	1834 (0.10%)	32 (0.12%)
Hypertension treated w/pills	187 (3.66%)	1194 (3.35%)	42885 (3.18%)	670 (3.54%)
COPD <sup>5</sup>	32 (0.85%)	100 (0.39%)	6878 (0.92%)	90 (0.72%)
Macular degeneration <sup>6</sup>	51 (0.83%)	252 (0.62%)	16296 (1.33%)	190 (0.96%)
Dementia <sup>6</sup>	47 (0.76%)	215 (0.53%)	11722 (0.96%)	173 (0.87%)
Parkinson's disease <sup>6</sup>	7 (0.11%)	33 (0.08%)	2081 (0.17%)	35 (0.18%)

<sup>1</sup> The SRC Super Cohort includes all White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

<sup>2</sup> During the main WHI Study and the WHI Extension Study 2005-2010, pulmonary embolism includes only inpatient self-reports. During WHI Extension Study 2010-2020, pulmonary embolism includes both inpatient and outpatient self-reports.

<sup>3</sup> During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

<sup>4</sup> This outcome has not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

<sup>5</sup> Data only collected during the WHI Extension Study 2010-2020.

<sup>6</sup> Data only collected during the WHI Extension Studies 2005-2020.